1. Home
  2. CPAY vs ICUCW Comparison

CPAY vs ICUCW Comparison

Compare CPAY & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPAY
  • ICUCW
  • Stock Information
  • Founded
  • CPAY 1986
  • ICUCW N/A
  • Country
  • CPAY United States
  • ICUCW United States
  • Employees
  • CPAY N/A
  • ICUCW 19
  • Industry
  • CPAY EDP Services
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • Sector
  • CPAY Technology
  • ICUCW Health Care
  • Exchange
  • CPAY Nasdaq
  • ICUCW Nasdaq
  • Market Cap
  • CPAY N/A
  • ICUCW N/A
  • IPO Year
  • CPAY 2010
  • ICUCW 2021
  • Fundamental
  • Price
  • CPAY $324.70
  • ICUCW $0.03
  • Analyst Decision
  • CPAY Buy
  • ICUCW
  • Analyst Count
  • CPAY 14
  • ICUCW 0
  • Target Price
  • CPAY $397.17
  • ICUCW N/A
  • AVG Volume (30 Days)
  • CPAY 471.6K
  • ICUCW N/A
  • Earning Date
  • CPAY 05-06-2025
  • ICUCW N/A
  • Dividend Yield
  • CPAY N/A
  • ICUCW N/A
  • EPS Growth
  • CPAY 6.08
  • ICUCW N/A
  • EPS
  • CPAY 14.26
  • ICUCW N/A
  • Revenue
  • CPAY $4,045,005,000.00
  • ICUCW N/A
  • Revenue This Year
  • CPAY $12.92
  • ICUCW N/A
  • Revenue Next Year
  • CPAY $10.54
  • ICUCW N/A
  • P/E Ratio
  • CPAY $22.98
  • ICUCW N/A
  • Revenue Growth
  • CPAY 6.68
  • ICUCW N/A
  • 52 Week Low
  • CPAY $247.10
  • ICUCW N/A
  • 52 Week High
  • CPAY $400.81
  • ICUCW N/A
  • Technical
  • Relative Strength Index (RSI)
  • CPAY 53.38
  • ICUCW N/A
  • Support Level
  • CPAY $313.59
  • ICUCW N/A
  • Resistance Level
  • CPAY $333.54
  • ICUCW N/A
  • Average True Range (ATR)
  • CPAY 8.99
  • ICUCW 0.00
  • MACD
  • CPAY 2.54
  • ICUCW 0.00
  • Stochastic Oscillator
  • CPAY 86.51
  • ICUCW 0.00

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: